• HR Defects and Chemotherapy Response in Malignant Mesothelio

  2026-06-29

  Borchert et al. (2019) reveal that homologous recombination repair (HRR) deficiencies, termed 'BRCAness,' are frequent in malignant pleural mesothelioma and can predict susceptibility to PARP inhibitor-based therapies. Their gene expression profiling suggests new biomarker-driven strategies for improving outcomes in a cancer type often resistant to conventional chemotherapy.

• Biotin-XX Tyramide: Enabling Precision Cell Surface Proteomi

  2026-06-29

  This thought-leadership article explores how Biotin-XX Tyramide Reagent transforms cell surface proteome mapping, with mechanistic insight from landmark neuroscience studies. It provides translational researchers with workflow guidance, strategic context, and a differentiated perspective, linking protocol optimization to emerging questions in neurobiology and disease.

• Peroxidasin Drives Glycolytic Reprogramming in Glioblastoma

  2026-06-28

  This study identifies peroxidasin (PXDN) as a key driver of glycolytic metabolism and malignant progression in glioblastoma through modulation of LDHA. These findings highlight PXDN as a candidate biomarker and potential therapeutic target for addressing the metabolic vulnerabilities of glioblastoma.

• EZ Cap™ Firefly Luciferase mRNA: Optimized Cap 1 Reporter To

  2026-06-27

  EZ Cap™ Firefly Luciferase mRNA provides robust, sustained luminescence for bioluminescent reporter assays thanks to its Cap 1 structure and optimized poly(A) tail. This construct enables superior mRNA delivery, stability, and translation efficiency in both in vitro and in vivo workflows. APExBIO's formulation supports high-sensitivity molecular biology applications.

• Cyclophilin A Dictates Cyclosporin A Immunosuppression in Mi

  2026-06-26

  The reference study demonstrates that cyclophilin A is essential for the immunosuppressive effects of Cyclosporin A, as mice lacking cyclophilin A (Ppia-/-) are resistant to Cyclosporin-mediated inhibition of T-cell activation. These findings clarify the molecular specificity of Cyclosporin A action, with direct implications for transplantation immunology and research model design.

• Doxycycline in Research: Protocols and Innovations in Cancer

  2026-06-26

  Doxycycline, a tetracycline antibiotic, is transforming experimental cancer and antimicrobial research with dual metalloproteinase inhibition and antiproliferative effects. This guide demystifies advanced workflows and troubleshooting strategies, with actionable insights from the latest nanocarrier-based cancer therapy innovations.

• Imipramine: Tricyclic Antidepressant Enabling Autophagy Rese

  2026-06-25

  Imipramine is a tricyclic antidepressant with robust autophagy-inducing and apoptosis-modulating properties, making it central to cancer and neuroprotection studies. Its nanomolar affinity for serotonin transporters and ability to trigger cell death in HL-60 and U-87MG cell lines are well-documented. APExBIO offers Imipramine (BA2970) as a research-grade reagent with validated stability protocols.

• N4-Acetylcytidine: Structural Insights & Innovation in RNA R

  2026-06-25

  Explore the unique role of N4-Acetylcytidine in RNA structure-function analysis, with an emphasis on novel structural findings and their impact on advanced assay design. This article provides a deeper, mechanism-driven perspective for RNA epigenetics research.

• Phosphoenolpyruvate Restricts cGAS-Driven Inflammation in Ag

  2026-06-24

  This article reviews the discovery that phosphoenolpyruvate (PEP), a glycolytic metabolite, functions as an intrinsic inhibitor of the cGAS–STING pathway, thereby limiting chronic inflammation and promoting healthy aging. The findings highlight metabolic intermediates as direct modulators of inflammatory signaling, with significant implications for research on aging, neurodegeneration, and metabolic regulation.

• Resiniferatoxin (RTX): Optimizing TRPV1 Modulation in Pain M

  2026-06-23

  Resiniferatoxin (RTX) stands out as an ultra-potent TRPV1 agonist, enabling unprecedented control of sensory neuron desensitization and analgesia in preclinical models. This guide distills key protocol enhancements, troubleshooting strategies, and actionable insights for maximizing RTX’s research impact—especially in pain and neuroinflammation studies.

• PKH26 Red Fluorescent Cell Linker Kit: Technical Guide & Pro

  2026-06-23

  The PKH26 Red Fluorescent Cell Linker Kit enables stable, long-term red fluorescent labeling of cell membranes, supporting reliable cell tracing and proliferation assays in both in vitro and in vivo experiments. It is not suitable for intracellular or non-membrane applications, and optimal results require strict protocol adherence.

• Erlotinib (SKU A3397): Data-Driven EGFR Inhibition in Cancer

  2026-06-22

  This article delivers scenario-based, evidence-backed guidance on optimizing cell viability and cytotoxicity assays with Erlotinib (SKU A3397). By addressing real-world challenges in EGFR signaling inhibition, the piece showcases how APExBIO's Erlotinib enables reproducible, high-sensitivity experiments and reliable data for cancer research.

• O-propargyl-puromycin: Translational Insights for B Cell Imm

  2026-06-22

  This thought-leadership article explores how O-propargyl-puromycin (OPP) empowers translational researchers to precisely quantify nascent protein synthesis, with a mechanistic focus on B cell immunity and mitochondrial regulation. It synthesizes recent advances in RNA-binding protein research, highlights best-in-class assay strategies, and sets a forward-looking agenda for innovation at the intersection of proteomics, immunology, and cellular metabolism.

• Strategic COX-2 Pathway Modulation: Lumiracoxib in Muscle Re

  2026-06-21

  This thought-leadership article explores how temporally precise, selective inhibition of the cyclooxygenase-2 (COX-2) pathway—using APExBIO's Lumiracoxib—can strategically inform translational research in vascular injury and muscle regeneration. Drawing on recent mechanistic studies, it provides actionable protocols, discusses competitive advantages, and offers a forward-looking perspective for researchers targeting inflammation and revascularization.

• Myriocin as a Serine Palmitoyltransferase Inhibitor: Experim

  2026-06-20

  Myriocin is a gold-standard serine palmitoyltransferase inhibitor, enabling precise interrogation of sphingolipid metabolism, cancer biology, and immunological signaling. This guide details optimized workflows, troubleshooting strategies, and translational insights for deploying Myriocin in advanced research, highlighting APExBIO's commitment to reagent quality and reproducibility.

451 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page